GB2607584B - Composition and method of treatment - Google Patents

Composition and method of treatment Download PDF

Info

Publication number
GB2607584B
GB2607584B GB2107966.0A GB202107966A GB2607584B GB 2607584 B GB2607584 B GB 2607584B GB 202107966 A GB202107966 A GB 202107966A GB 2607584 B GB2607584 B GB 2607584B
Authority
GB
United Kingdom
Prior art keywords
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2107966.0A
Other languages
English (en)
Other versions
GB2607584A (en
GB202107966D0 (en
Inventor
Jan Oostwouder Cornelis
Chanderprekash Jaikrishne Kanhai Robert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stichting Medische Kliniek Velsen
Original Assignee
Stichting Medische Kliniek Velsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Medische Kliniek Velsen filed Critical Stichting Medische Kliniek Velsen
Priority to GB2107966.0A priority Critical patent/GB2607584B/en
Publication of GB202107966D0 publication Critical patent/GB202107966D0/en
Priority to EP22730986.1A priority patent/EP4346791A1/en
Priority to US18/566,968 priority patent/US20240269109A1/en
Priority to JP2023575452A priority patent/JP2024520767A/ja
Priority to PCT/IB2022/055134 priority patent/WO2022254363A1/en
Priority to CN202280046171.0A priority patent/CN117715633A/zh
Publication of GB2607584A publication Critical patent/GB2607584A/en
Application granted granted Critical
Publication of GB2607584B publication Critical patent/GB2607584B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB2107966.0A 2021-06-03 2021-06-03 Composition and method of treatment Active GB2607584B (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GB2107966.0A GB2607584B (en) 2021-06-03 2021-06-03 Composition and method of treatment
PCT/IB2022/055134 WO2022254363A1 (en) 2021-06-03 2022-06-01 Lidocaine or articaine for treating covid-19, autoimmune disease or cytokine storm response
US18/566,968 US20240269109A1 (en) 2021-06-03 2022-06-01 Lidocaine or articaine for treating covid-19, autoimmune disease or cytokine storm response
JP2023575452A JP2024520767A (ja) 2021-06-03 2022-06-01 Ｃｏｖｉｄ－１９、自己免疫疾患、又はサイトカインストーム応答を処置するためのリドカイン又はアルチカイン
EP22730986.1A EP4346791A1 (en) 2021-06-03 2022-06-01 Lidocaine or articaine for treating covid-19, autoimmune disease or cytokine storm response
CN202280046171.0A CN117715633A (zh) 2021-06-03 2022-06-01 用于治疗covid-19、自身免疫性疾病或细胞因子风暴反应的利多卡因或阿替卡因

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2107966.0A GB2607584B (en) 2021-06-03 2021-06-03 Composition and method of treatment

Publications (3)

Publication Number Publication Date
GB202107966D0 GB202107966D0 (en) 2021-07-21
GB2607584A GB2607584A (en) 2022-12-14
GB2607584B true GB2607584B (en) 2024-07-17

Family

ID=76838703

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2107966.0A Active GB2607584B (en) 2021-06-03 2021-06-03 Composition and method of treatment

Country Status (6)

Country Link
US (1) US20240269109A1 (cg-RX-API-DMAC7.html)
EP (1) EP4346791A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520767A (cg-RX-API-DMAC7.html)
CN (1) CN117715633A (cg-RX-API-DMAC7.html)
GB (1) GB2607584B (cg-RX-API-DMAC7.html)
WO (1) WO2022254363A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2639834A (en) * 2024-03-22 2025-10-08 Remicine Ip B V Composition and method of treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103142643A (zh) * 2013-03-22 2013-06-12 新疆医科大学第一附属医院 Alha心脏停搏液及其制备方法
CN104127397A (zh) * 2014-08-19 2014-11-05 董颖颖 一种治疗急慢性过敏性及充血性皮肤病的药物及方法
CN111150738A (zh) * 2020-02-06 2020-05-15 西安交通大学医学院第二附属医院 一种治疗皮肤病的外用药物
RU2742505C1 (ru) * 2020-10-01 2021-02-08 Общество с ограниченной ответственностью "Институт термологии" Аэрозоль для инвазивной механической вентиляции легких при covid-19
WO2021201680A1 (en) * 2020-03-31 2021-10-07 Hasan Djohan Treatment of hyperinflammatory syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008550A1 (en) * 1992-10-09 1994-04-28 The Procter & Gamble Company Anaesthetic compositions
JP5111117B2 (ja) * 2005-12-22 2012-12-26 興和株式会社 ステロイドの経時的安定性が改善された外用製剤
TWI464148B (zh) * 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
TWI395593B (zh) * 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
CN106692120A (zh) * 2016-12-15 2017-05-24 刘力 利多卡因的药物组合物及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103142643A (zh) * 2013-03-22 2013-06-12 新疆医科大学第一附属医院 Alha心脏停搏液及其制备方法
CN104127397A (zh) * 2014-08-19 2014-11-05 董颖颖 一种治疗急慢性过敏性及充血性皮肤病的药物及方法
CN111150738A (zh) * 2020-02-06 2020-05-15 西安交通大学医学院第二附属医院 一种治疗皮肤病的外用药物
WO2021201680A1 (en) * 2020-03-31 2021-10-07 Hasan Djohan Treatment of hyperinflammatory syndrome
RU2742505C1 (ru) * 2020-10-01 2021-02-08 Общество с ограниченной ответственностью "Институт термологии" Аэрозоль для инвазивной механической вентиляции легких при covid-19

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bone Marrow Transplantation, vol. 28, no. 1, Voltarelli J C et al., "Beneficial effect of intravenous lidocaine in cutaneous chronic graft-versus-host disease secondary to donor lymphocyte infusion", p. 97-99. *
LUNG, vol. 182, no. 1, 2004, Huang T K et al., "Surfactant Lavage with Lidocaine Improves Pulmonary Function in Piglets after HCl-Induced Acute Lung Injury", p. 15-25. *
Trials, vol. 22, no. 1, 2021, Muller Marie et al., "Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial.", p. 131. *

Also Published As

Publication number Publication date
GB2607584A (en) 2022-12-14
CN117715633A (zh) 2024-03-15
EP4346791A1 (en) 2024-04-10
GB202107966D0 (en) 2021-07-21
US20240269109A1 (en) 2024-08-15
JP2024520767A (ja) 2024-05-24
WO2022254363A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
FI4126066T3 (fi) Koostumuksia ja menetelmiä lihasdystrofian hoitoon
IL300067A (en) Preparations and methods for the treatment of cancers
IL309952A (en) Compositions and methods for treating melanoma
EP4110369A4 (en) TREATMENT METHODS AND RELATED COMPOSITIONS
IL312583A (en) A preparation for the treatment and prevention of COVID-19
IL315503A (en) Treatment methods
IL320711A (en) Treatment methods
GB2607584B (en) Composition and method of treatment
GB202201824D0 (en) Methods of treatment
HUE069670T2 (hu) Készítmény és módszer a sclerosis multiplex kezelésére
GB201913122D0 (en) Compositions and methods for treatment of cholangiocarcinoma
GB202302434D0 (en) Compositions and method for the treatment of onychomycosis
GB202119051D0 (en) Wingsail and method of use
GB201810923D0 (en) Compositions and method of treatment
GB202317431D0 (en) Arrangement and method for treatment of fish
GB202317378D0 (en) Composition and methods of treatment
GB202201819D0 (en) Methods of treatment
GB202201825D0 (en) Methods of treatment
IL288415A (en) Combinations and methods for the treatment of hemochromatosis
GB202318443D0 (en) Compositions and methods of treatment
GB202218196D0 (en) Compositions and methods of treatment
GB202000248D0 (en) Compositions and methods of treatment
GB201913124D0 (en) Compositions and methods for treatment of cholangiocarcinoma
GB201913121D0 (en) Compositions and methods for treatment of cholangiocarcinoma
GB202509578D0 (en) Composition and method of treatment